Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 May;63(5):794–798. doi: 10.1038/bjc.1991.176

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

D I Jodrell 1, I E Smith 1, J L Mansi 1, M C Pearson 1, G Walsh 1, S Ashley 1, H D Sinnett 1, J A McKinna 1
PMCID: PMC1972405  PMID: 2039705

Abstract

Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer. We have compared MMM (mitozantrone 8 mg m-2 i.v. q 3 weekly, methotrexate 35 mg m-2 i.v. q 3 weekly, mitomycin-C 8 mg m-2 i.v. q 6 weekly) with CMF (cyclophosphamide 100 mg orally, days 1-14, methotrexate 35 mg m-2 i.v., days 1 and 8, 5-FU 1,000 mg i.v., days 1 and 8, q 4 weekly), each regimen with folinic acid rescue, in a randomised trial, 29/57 evaluable patients treatment with MMM achieved an objective response (51%) compared with 33/55 treated with CMF (60%). Overall median survival was 16 months for MMM and 12 months for CMF. Subjective toxicity was low for both regimens and the only significant difference was in incidence of diarrhoea (50% for CMF vs 21% for MMM). Haematological toxicity was similar, leading to treatment delays and/or dose reductions in 35% patients with CMF vs 43% with MMM. Thrombocytopenia was significantly increased in MMM (34% vs 14%). No clinical cardiotoxicity was seen, but a significant reduction in left ventricular ejection fraction occurred in four patients on CMF vs 2 on MMM. MMM is an active, well tolerated new chemotherapy regimen for advanced/metastatic breast carcinoma with an efficacy and toxicity spectrum very similar to CMF.

Full text

PDF
794

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Weinberg V., Perloff M., Weiss R., Perry M., Korzun A., Ginsberg S., Holland J. F. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol. 1987 Oct;5(10):1523–1533. doi: 10.1200/JCO.1987.5.10.1523. [DOI] [PubMed] [Google Scholar]
  2. Benjamin R. S., Chawla S. P., Ewer M. S., Carrasco C. H., Mackay B., Holmes F. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs. 1985;3(2):117–121. doi: 10.1007/BF00174158. [DOI] [PubMed] [Google Scholar]
  3. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981 Jan 1;304(1):10–15. doi: 10.1056/NEJM198101013040103. [DOI] [PubMed] [Google Scholar]
  4. Brambilla C., De Lena M., Rossi A., Valagussa P., Bonadonna G. Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J. 1976 Apr 3;1(6013):801–804. doi: 10.1136/bmj.1.6013.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coates A., Gebski V., Bishop J. F., Jeal P. N., Woods R. L., Snyder R., Tattersall M. H., Byrne M., Harvey V., Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987 Dec 10;317(24):1490–1495. doi: 10.1056/NEJM198712103172402. [DOI] [PubMed] [Google Scholar]
  6. Cummings F. J., Gelman R., Horton J. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol. 1985 Jul;3(7):932–940. doi: 10.1200/JCO.1985.3.7.932. [DOI] [PubMed] [Google Scholar]
  7. Hayes D. F., Henderson I. C. CAF in metastatic breast cancer: standard therapy or another effective regimen? J Clin Oncol. 1987 Oct;5(10):1497–1499. doi: 10.1200/JCO.1987.5.10.1497. [DOI] [PubMed] [Google Scholar]
  8. Henderson I. C., Allegra J. C., Woodcock T., Wolff S., Bryan S., Cartwright K., Dukart G., Henry D. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989 May;7(5):560–571. doi: 10.1200/JCO.1989.7.5.560. [DOI] [PubMed] [Google Scholar]
  9. Kennedy J. W., Sorensen S. G., Ritchie J. L., Folland E. D., Hamilton G. W. Radionuclide angiography for the evaluation of anthracycline therapy. Cancer Treat Rep. 1978 Jun;62(6):941–943. [PubMed] [Google Scholar]
  10. Muss H. B., White D. R., Richards F., 2nd, Cooper M. R., Stuart J. J., Jackson D. V., Rhyne L., Spurr C. L. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial. Cancer. 1978 Nov;42(5):2141–2148. doi: 10.1002/1097-0142(197811)42:5<2141::aid-cncr2820420509>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  11. Posner L. E., Dukart G., Goldberg J., Bernstein T., Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs. 1985;3(2):123–132. doi: 10.1007/BF00174159. [DOI] [PubMed] [Google Scholar]
  12. Smalley R. V., Lefante J., Bartolucci A., Carpenter J., Vogel C., Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3(2):209–220. doi: 10.1007/BF01803563. [DOI] [PubMed] [Google Scholar]
  13. Stuart-Harris R. C., Bozek T., Pavlidis N. A., Smith I. E. Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol. 1984;12(1):1–4. doi: 10.1007/BF00255899. [DOI] [PubMed] [Google Scholar]
  14. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  15. Tormey D. C., Gelman R., Band P. R., Sears M., Rosenthal S. N., DeWys W., Perlia C., Rice M. A. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1982 Oct 1;50(7):1235–1244. doi: 10.1002/1097-0142(19821001)50:7<1235::aid-cncr2820500703>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES